Company Page

pHLIP, Inc. is a clinical-stage biopharmaceutical company pioneering a proprietary peptide-based targeted delivery platform. The company's pH-Low Insertion Peptide (pHLIP) technology exploits the acidic microenvironment of diseased tissues to selectively target and deliver therapeutic and imaging agents to cancer cells, activated macrophages, and fibroblasts. The platform enables both surface anchoring and intracellular delivery of drugs, gene therapeutics, and nanoparticles. pHLIP has exclusive worldwide commercial rights to technology licensed from Yale University, University of Rhode Island, and Memorial Sloan Kettering Cancer Center.

Company Founded in 2014

Healthtech & Biotech